ClinicalTrials.gg
Not yet recruitingNCT07950150Updated Nov 20, 2026

Pomegranate-Prebiotic Supplementation for Sarcopenic Obesity

An interventional study of Pomegranate Fruit Extract and Pomegranate Fruit Extract in Sarcopenic Obesity, Sarcopenia and Obesity, sponsored by The Hong Kong Polytechnic University. Not yet recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Basic science

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 83 studies in Sarcopenia with a site in China — 47 open to participants now, 52 under way, 4 of them phase 3. Sarcopenia · China.

Planned enrollment
49th of 52
30 · median 110
Started
2026
with 15 others
No phase
42 of 83
20 open now
Primary completion
2026-12
later than 21 of 51 live
Registered
83rd of 83
by date
Lead sponsor
3 of 83
The Hong Kong Polytechnic University

Among the 83 studies in Sarcopenia with a site in China, this one is the 49th largest by planned enrollment of the 52 interventional ones that give a count, is one of 16 that started in 2026, is one of 42 with no phase, reaches primary completion later than 21 of the 51 other live ones, and was the 83rd registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 417 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

47 of the 83 studies in Sarcopenia with a site in China are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Sarcopenia with a site in China, or all of them as a file.
02

Study summary

Sarcopenic obesity (SO) in older adults involves the co-occurrence of skeletal muscle decline and excessive body fat. This project investigates the gut-muscle axis, specifically how gut bacteria convert dietary polyphenols (such as ellagic acid found in pomegranates) into a muscle-protecting metabolite called Urolithin A (UA). This study is a randomized crossover pilot trial in 30 older adults with SO. It tests whether combining a pomegranate extract supplement with a prebiotic (Fructo-oligosaccharides, or FOS) increases the body's production of UA more effectively than pomegranate extract alone over a 7-day period.

Read the detailed description

Background and Rationale Sarcopenic obesity (SO) is a major public health challenge that significantly increases the risk of frailty, functional dependence, and metabolic comorbidities in aging populations. Current lifestyle and nutritional interventions often fail to address the underlying mitochondrial dysfunction and chronic low-grade inflammation central to the pathogenesis of SO. Recently, the gut-muscle axis has emerged as a therapeutic target. Urolithin A (UA) is a gut-derived microbial metabolite synthesized from dietary ellagitannins and ellagic acid (abundant in pomegranates) that activates mitophagy and improves mitochondrial health in skeletal muscle. However, UA synthesis is highly variable and depends on individual gut microbial composition, which is often compromised in older adults with obesity and sarcopenia (dysbiosis). Recent evidence suggests that prebiotics like Fructo-oligosaccharides (FOS) can promote the specific bacterial strains (Bifidobacterium and Enterococcus species) required for the two-step bioconversion of ellagic acid into UA.

This is a clinical pilot trial designed to test the feasibility and biological efficacy of a synergistic nutritional intervention. A total of 30 older adults diagnosed with SO will be enrolled in a randomized crossover trial. Each participant will undergo two 7-day intervention periods separated by a 14-day washout period.

Intervention A includes pomegranate extract alone (yielding 200 mg/day of ellagic acid). Intervention B includes pomegranate extract (yielding 200 mg/day of ellagic acid) combined with FOS prebiotic powder (5 g/day).

Because each participant serves as their own control, the crossover design eliminates the confounding effect of individual variability in baseline gut microbiome composition. The primary outcome is the within-participant difference in 24-hour urinary UA excretion (normalized to creatinine) between the combined intervention and the single-component intervention. Secondary outcomes include changes in fecal urolithin concentrations and shifts in gut microbiota composition assessed via 16S rRNA sequencing. Findings will inform the design of a fully powered randomized controlled trial testing this cost-effective synbiotic strategy for managing SO.

03

Conditions studied

  • Sarcopenic Obesity
  • Sarcopenia
  • Obesity
  • Muscle Weakness
  • Dysbiosis
  • Aging
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 65 years or older.
  • Confirmed diagnosis of Sarcopenic Obesity (SO) according to 2022 ESPEN-EASO consensus and AWGS criteria:
  • Obesity Component: BF% ≥25% (men) / ≥35% (women); OR ≥23kg/m2; OR waist circumference >90cm (men) / >80cm (women).
  • Sarcopenia Component: Low relative skeletal muscle mass combined with low handgrip strength (\<28 kg men / \<18kg women) and/or low physical performance (5-time chair stand ≥12s or gait speed \<1.0m/s).
  • Able and willing to provide .
  • Willing and able to comply with all study procedures, dietary supplementation, and sample collections (24-hour urine and fecal samples).

Exclusion criteria

Exclusion Criteria:

  • Current regular intake of pomegranate, ellagitannin, or prebiotic supplements.
  • Known or allergy to pomegranate or fructo-oligosaccharides (FOS).
  • History of renal diseases, renal replacement therapy, active cancer, severe cognitive impairment, or severe cardiac or hepatic dysfunction.
  • Exposure to systemic antibiotics within 3 months prior to enrollment.
  • Current participation in any other active interventional clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Pomegranate Extract Alone (Active Control)

    Participants will complete a 7-day intervention period receiving dietary supplementation with pomegranate extract alone.

    Dietary Supplement: Pomegranate Fruit Extract

  • Experimental
    Pomegranate Extract + Fructo-oligosaccharides (FOS)

    Participants will complete a 7-day intervention period receiving dietary supplementation with pomegranate extract in combination with FOS prebiotic powder.

    Dietary Supplement: Pomegranate Fruit Extract · Dietary Supplement: Fructo-oligosaccharides (FOS) Prebiotic

Interventions

  • Dietary supplementPomegranate Fruit Extract

    Two tablets daily of commercial pomegranate extract (Puritan's Pride), providing a total daily dose of 500 mg pomegranate fruit extract containing 200 mg ellagic acid (EA). Administered orally for 7 consecutive days.

  • Dietary supplementPomegranate Fruit Extract

    Two tablets daily of commercial pomegranate extract (Puritan's Pride), providing a total daily dose of 500 mg pomegranate fruit extract containing 200 mg ellagic acid (EA). Administered orally for 7 consecutive days.

  • Dietary supplementFructo-oligosaccharides (FOS) Prebiotic

    Two teaspoons (5 g/day) daily of Source Naturals FOS Powder. Provided as pre-measured daily sachets of bulk powder to be mixed with water, juice, or food and consumed orally for 7 consecutive days.

06

What researchers measure

Primary outcomes

  1. 24-Hour Urinary Urolithin A Excretion

    Within-participant difference in 24-hour total urinary urolithin A excretion normalized to urinary creatinine between the Pomegranate Extract + FOS intervention period and the Pomegranate Extract Alone intervention period. Measured via UHPLC-MS/MS.

    Time frame: Day 7 of Period 1 and Day 7 of Period 2 (at the end of each 7-day intervention period).

Secondary outcomes

  1. 24-Hour Total Urinary Urolithins Profile

    Total excretion of urolithin metabolites and intermediates (including urolithin B and urolithin C) measured in 24-hour batch urine samples using UHPLC-MS/MS.

    Time frame: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.

  2. Gut Microbiota Composition

    Relative abundance and community structure of target gut bacteria (including Bifidobacterium species and urolithin-converting taxa) determined by 16S rRNA gene sequencing (V3-V4 hypervariable region) on an Illumina MiSeq platform.

    Time frame: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.

  3. Fecal Urolithin Concentrations

    Concentrations of urolithin A, urolithin B, and urolithin C in self-collected homogenized fecal samples, extracted and quantified via UHPLC-MS/MS.

    Time frame: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2026, 1 month later.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 1 month is below that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 20, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950150
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 20, 2026

Study contacts

Ka Hei Kenneth Lo, PhD
Contact
kenneth.kh.lo@polyu.edu.hk
852-3400-8778

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion